Sensorium Therapeutics
Jerry Rosenbaum has had an extensive career in the medical and research fields. Jerry began their career in 1974 as the Stanley Cobb Professor of Psychiatry and a Resident at Massachusetts General Hospital and Harvard Medical School. In 2002, they were appointed as the Director Emeritus and Senior Advisor of the Center for Anxiety and Traumatic Stress Disorders (CATSD) at Massachusetts General Hospital. In 2016, they co-founded Psy Therapeutics, Inc., where they serve as a Co-Founder and Director. In 2020, they co-founded Sensorium Therapeutics and was appointed as the Director of the Center for the Neuroscience of Psychedelics at the Massachusetts General Hospital Research Institute. Most recently, in 2022, they co-founded Entheos Labs, where they serve as a Co-founder and Director.
Jerry Rosenbaum attended Yale College from 1965 to 1969 and obtained a BA in American Studies. Jerry then attended Yale University School of Medicine from 1969 to 1973.
Sensorium Therapeutics
Founded by world-class researchers, clinicians, and thought leaders from Massachusetts General Hospital and Harvard University, Sensorium Therapeutics is a biotechnology company leveraging cutting-edge chemistry, neuroscience, and machine learning to develop nature-derived psychoactive medicines for mental health. Inspired by the real-world human benefits of plants and fungi, Sensorium’s groundbreaking Biodynamic Discovery Platform leverages cutting-edge chemistry, neuroscience, and machine learning to reproduce, adapt, and enhance targeted molecules to elevate their utility as modern medicines that can deliver transformational benefits to patients around the world.